Two things:
I've re-read the results announcement from the phase 2 trial (late 2014) and can find no reference to match the comment "targets mechanisims underlying the disorder rather than a symptomatic medication".
To a "scientific heathen" like myself, it sounds like a big deal. I'm interested in exploring this point some more and will be doing so.
Secondly, I've had shares in various companies that have been in and out of the (lesser) ASX indices over the years. I've never seen any evidence of so-called index selling and haven't seen anything here with NEU that indicates it happened other than might in other than an insignificant fashion.
Two things: I've re-read the results announcement from the phase...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.71 |
Change
-0.590(3.41%) |
Mkt cap ! $2.135B | |||
| Open | High | Low | Value | Volume |
| $17.50 | $17.55 | $16.57 | $10.01M | 594.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 598 | $16.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.87 | 1676 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |